

July 18, 2000

Name

Eran M-Hale

07-20-00

Please type a plus sign (+) inside this box ☒Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 13020-10

First Inventor or Application Identifier Lincoln

Title Automatic Genotype Determination

Express Mail Label No. EL301953995US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for free processing)
2. ☒ Specification [Total Pages 33]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 6]
4. Oath or Declaration [Total Pages 3]
- a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of
(when there is an assignee) ☐ Attorney
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 ☐ Citations
11. ☒ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☐ Small Entity ☐ Statement filed in prior application,
Statement(s) ☐ Status still proper and desired
(PTO/SB/09-12)
14. ☐ Certified Copy of Priority Document(s)
(If foreign priority is claimed)
15. ☐ Other: _____

*NOTE FOR ITEMS 1, 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY
FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.57), EXCEPT
IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.51).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. 09,088,820

Prior application information: Examiner Jeffrey Fredman Group / Art Unit: 1655

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied
under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by
reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name David A. Kalow

Kalow & Springut LLP

Address 488 Madison Avenue, 19th Floor

City New York State New York Zip Code 10022

Country United States Telephone 212 813 1600 Fax 212 813 9600

Name (Print/Type) Franklin S. Abrams Registration No. (Attorney/Agent) 43,457

Signature Franklin S. Abrams Date 7/18/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any
comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office,
Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,
Box Patent Application, Washington, DC 20231.

10666 U.S. PTO
07/18/00

09616179 071800

07/18/00
09616179

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lincoln *et al.*

Attorney Docket: 13020-10

Serial No.: not yet assigned

Examiner (from parent): Fredman, J.

Date Filed: herewith

Group Art Unit (from parent): 1655

For: AUTOMATIC GENOTYPE DETERMINATION

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, NY 10022

July 18, 2000

Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination on the merits, please amend the application identified above as follows.

IN THE SPECIFICATION

At page 1, line 5, immediately after the phrase "This application is" please insert: -- a continuation of application serial number 09/088,820, which is a continued prosecution application of application serial number 09/088,820, filed June 2, 1998, which is --.

At page 1, line 10, immediately after the phrase "This immediate parent application" please insert: -- (application serial number 08/173,173)- --.

REMARKS

A final office action for the parent application Serial No. 09/088,820 was mailed on January 24, 2000. Accordingly, Applicants have enclosed herewith a three-month extension of time along with a check for \$870.00. Thus the present continuation application is filed herewith

Certificate of Express Mail Under 37 CFR 1.10

I hereby declare that this correspondence is being deposited with the United States Postal Service via Express Mail Label No. E1301953995US in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231

July 18, 2000
Date

Erin M. Hule
Name

00618178-071800

before the patenting, abandonment or termination of proceedings on application Serial No. 09/088,820.

If resolution of any remaining issue is required prior to examination of the application, it is respectfully requested that the Examiner contact Applicants' undersigned attorney at the telephone number provided below.

Respectfully submitted,



Franklin S. Abrams
Registration No. 43,457
Attorney for Applicants

Telephone (212)813 1600

T:\PATENTS\Applications\13020-10\preliminamend.wpd

09618178-071800

AUTOMATIC GENOTYPE DETERMINATION

09548178 071800
043120 82181960

Inventors: Stephen E. Lincoln
Michael R. Knapp

Certificate of Express Mail Under 37 CFR 1.10

I hereby declare that this correspondence is being deposited with the United States Postal Service via Express Mail Label No. EL301953995US, in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231.

July 18, 2000
Date

Evan McHale
Name

Attorney Docket 1471/108

AUTOMATIC GENOTYPE DETERMINATION

Cross Reference to Related Applications

10
20
25
This application is a continuation of application serial no. 08/362,266, filed December 22, 1994, which is a continuation in part of application serial no. 08/173,173, filed December 23, 1993, which is for an invention entitled "Automatic Genotype Determination," by Stephen E. Lincoln and Michael P. Knapp. This immediate parent application is a continuation in part of application serial no. 07/775,786, filed October 11, 1991, for an invention entitled "Nucleic Acid Typing by Polymerase Extension of Oligonucleotides using Terminator Mixtures," by P. Goelet, M. Knapp, and S. Anderson, which in turn is a continuation in part of application serial no. 07/664,837, filed March 5, 1991. Immediate parent application serial no. 08/173,173 is also a continuation in part of application serial no. 08/162,397, filed December 6, 1993, for an invention entitled "Method for Immobilization of Nucleic Acid Molecules" by T. Nikiforov and M. Knapp, and of application serial no. 08/155,746, filed November 23, 1993, for an invention entitled "Method for Generating Single-Stranded DNA Molecules" by T. Nikiforov and M. Knapp, and of application serial no. 08/145,145, filed November 3, 1993, for an invention entitled "Single Nucleotide Polymorphisms and their use in Genetic Analysis" by M. Knapp and P. Goelet. All of these related applications are hereby incorporated herein by reference.

Technical Field

The present invention relates to the methods and devices for determining the genotype at a locus within genetic material.

Summary of the Invention

The present invention provides in one embodiment a method of determining the genotype at a locus within genetic material obtained from a biological sample. In accordance with this method, the material is reacted at the locus to produce a first reaction value indicative of the presence of a given allele at the locus. There is formed a data set including the first reaction value. There is also established a set of one or more probability distributions; these distributions associate hypothetical reaction values with corresponding probabilities for each genotype of interest at the locus. The first reaction value is applied to each probability distribution to determine a measure of the conditional probability of each genotype of interest at the locus. The genotype is then determined based on these measures.

In accordance with a further embodiment of this method, the material at the locus is subject to a second reaction to produce a second reaction value independently indicative of the presence of a second allele at the locus. A second data set is formed and the second reaction value is included in the second data set. Each probability distribution associates a hypothetical pair of first and second reaction

5
10

25
30

5 The foregoing methods have been employed with success
for automatic genotype determination based on assays using
genetic bit analysis (GBA). In such a case, each allele may
typically be a single specific nucleotide. In accordance
10 with GBA, a reaction is designed to produce a value that is
indicative of the presence of a specific allele at the locus
within the genetic material. In GBA, the approach is
typically to hybridize a specific oligonucleotide to the
genetic material at the locus immediately adjacent to the
nucleotide being interrogated. Next, DNA polymerase is
15 applied in the presence of differentially labelled
dideoxynucleoside triphosphates. The read-out steps detect
the presence of one or more of the labels which have become
covalently attached to the 3' end of the oligonucleotide.
Details are provided in Theo R. Nikiforov et al. "Genetic
20 Bit Analysis, a solid phase method for typing single
nucleotide polymorphisms," 22 Nucleic Acids Research, No.
20, 4167-4175 (1994), which is hereby incorporated herein by
reference. However, the present invention is also applicable
to other reaction systems for allele determination, such as
25 allele-specific hybridization (ASH), sequencing by
hybridization (CBH), oligonucleotide ligase assay (OLA), and
allele-specific amplification, using either the ligase chain
reaction (LCR) or the polymerase chain reactions (PCR). The
alleles assayed may be defined, for example, by a single
30 nucleotide, a pair of nucleotides, a restriction site, or
(at least in part) by its length in nucleotides.

In another embodiment of the invention, there is

provided a method of determining the genotype of a subject by reacting genetic material taken from the subject at selected loci. In this embodiment, each locus may be an identified single nucleotide or group of nucleotides, and there is produced with respect to each of the selected loci a reaction value indicative of the presence of a given allele at each of the selected loci. These reaction values are used to determine the genotype of the subject or alternatively a DNA sequence associated with a specific region of genetic material of the subject. (Indeed a set of genotypes for selected proximal loci may be used to specify a sequence of the genetic material.) In further embodiments, the loci are selected to provide one or more types of information concerning the subject, including inheritance of a trait, parentage, identity, and matching tissue with that of a donor. Alternatively, the loci may be spaced throughout the entire genome of subject to assist in characterizing the genome of the species of the subject.

In a further embodiment of the invention, there is provided a device for determining the genotype at a locus within genetic material obtained from a subject. The device of this embodiment has a reaction value generation arrangement for producing a first physical state, quantifiable as a first reaction value, indicative of the presence of a given allele at the locus, the value associated with reaction of the material at the locus. The device also has a storage arrangement for storing a data set including the first reaction value and other reaction values

5 obtained under comparable conditions. A distribution
establishment arrangement establishes a set of probability
distributions, including at least one distribution,
associating hypothetical reaction values with corresponding
probabilities for each genotype of interest at the locus. A
10 genotype calculation arrangement applies the first reaction
value to each pertinent probability distribution to
determine the conditional probability of each genotype of
interest at the locus. A genotype determination arrangement
determines the genotype based on data from the genotype
15 calculation arrangement.

In a further embodiment, the device may determine the
genotype at selected loci. In this embodiment, the reaction
generation arrangement can produce a reaction value
indicative of the presence of a given allele at each of the
selected loci and the data set includes reaction values
20 obtained with respect to each of the selected loci. The
genotype calculation arrangement applies reaction values
obtained with respect to each of the selected loci to each
pertinent probability distribution.

25 In another further embodiment, the device may determine
the genotype at a locus within genetic material from each of
a plurality of samples. In this embodiment, the reaction
generation arrangement can produce a reaction value
indicative of the presence of a given allele at the locus of
30 material obtained from each sample and the data set includes
reaction values obtained with respect to each sample. The
genotype calculation arrangement applies reaction values

obtained with respect to each sample to each pertinent probability distribution.

In each of these embodiments the reaction value generation arrangement may also include an arrangement for producing a second reaction value, independently indicative of the presence of a second allele at the locus. The storage arrangement then includes a provision for storing the second reaction value and other reaction values obtained under comparable conditions. The genotype calculation arrangement applies the first and second reaction values to each pertinent probability distribution to determine the probability of each genotype of interest at the locus. Each probability distribution may be of the type associating a hypothetical pair of first and second reaction values with a single probability of each genotype of interest. The locus may be a single nucleotide, and the reaction value generation arrangement may include an optical transducer to read reaction results and may determine, on a substantially concurrent basis, the reaction values with respect to each sample.

The distribution establishment arrangement may be configured to assign an initial probability distribution to the data set that would associate hypothetical reaction values with corresponding probabilities for each genotype of interest at the locus. The distribution establishment arrangement then invokes the genotype calculation means to use each initial probability distribution to determine initial conditional probabilities for a genotype of interest

5 at the locus. Thereafter the distribution establishment arrangement modifies each initial probability distribution, so that each modified distribution more accurately reflects the reaction values stored in the storage means.

10 The term "reaction value" as used in this description and the following claims may refer either to a single numerical value or to a collection of numbers associated with a physical state produced by the reaction. In the GBA method described in the Nikiforov article referred to above, e.g., optical signals are produced that may be read as a single numerical value. Alternatively, e.g., an optical signal may be simplified over time, and the reaction value may be the collection of samples of such a signal. It is also possible to form a scanned image, of one or a series of optical signals generated by GBA or other reaction methods, and to digitize this image, so that a collection of pixel values in all or a portion of the image constitutes a reaction value.

Brief Description of the Drawings

25 The foregoing aspects of the invention will be more readily understood by reference to the following detailed description, taken with respect to the following drawings, in which:

30 Fig. 1 is a diagram of a device in accordance with a preferred embodiment of the invention;

Fig. 2 is a diagram of the logical flow in accordance

with the embodiment of Fig. 1;

Fig. 3 is a graph of numeric reaction values (data) generated by the embodiment of Fig. 1 as well as the genotype determinations made by the embodiment from these data; and

Figs. 4-7 show probability distributions derived by the embodiment of Fig. 1 for three genotypes of interest (AA, AT, and TT) and a failure mode at a locus.

Fig. 8 is an example of the output of the device in Fig. 1.

Detailed Description of Specific Embodiments

The invention provides in preferred embodiments a method and device for genotype determination using genetic marker systems that produce allele-specific quantitative signals. An embodiment uses computer processing, employing computer software we developed and call "GetGenos", of data produced by a device we also developed to produce GBA data. The device achieves, among other things, the following:

- Fully automatic genotype determination from quantitative data. Off-line analysis of data pools is intended, although the software is fast enough to use interactively.
- Ability to examine many allele tests per DNA sample simultaneously. One genotype and confidence measure are produced from these data.
- A true probabilistic confidence measure (a LOD

score), properly calibrated, is produced for each genotype.

- Use of robust statistical methods: Noise reduction via selective data pooling and simultaneous search over points in a data pool, preventing bias.

- Maximal avoidance of arbitrary parameters, and thus insensitivity to great variation in input data. The small number of parameters that are required by the underlying statistical model are fit to the observed data, essentially using the data set as its own internal control.

- Flexibility for handling multiple data types. Essentially, only probability distribution calculations, described below, need to be calibrated to new data types. We expect that the invention may be applied to GBA, OLA, ASH, and RAPD-type markers.

Our current embodiment of the software is implemented in portable ANSI C, for easy integration into a custom laboratory information system. This code has been successfully run on:

- Macintosh
- Sun
- MS-DOS
- MS-Windows

In our current embodiment of the software, a number of consistency checks are performed for GBA data verification, using both the raw GBA values and the control wells.

Overall statistics for trend analysis and QC are computed. Brief "Genotype Reports" are generated, summarizing results for each data set, including failures. All data are output

in a convenient form for import into interactive statistical packages, such as DataDeskTM. The current implementation is presently restricted to 2-allele tests in diploids - the situation with present GBA applications.

Referring to Fig. 1, there is shown a preferred embodiment of a device in accordance with the present invention. The device includes an optical detector 11 to produce reaction values resulting from one or more reactions. These reactions assay for one or more alleles in samples of genetic material. We have implemented the detector 11 using bichromatic microplate reader model 348 and microplate stacker model 83 from ICN Biomedical, Inc., P.O. Box 5023, Costa Mesa, California 92626. The microplates are in a 96 well format, and the reader accommodates 20 microplates in a single processing batch. Accordingly the device of this embodiment permits large batch processing. The reactions in our implementation use GBA, as described above. The detector 11 is controlled by computer 12 to cause selected readout of reaction values from each well. The computer 12 is programmed to allow for multiple readout of the reaction value from a given well over a period of time. The values are stored temporarily in memory and then saved in database 14. Computer 13 accesses the database 14 over line 15 and processes the data in accordance with the procedure described below. Of course, computers 12 and 13 and database 14 may be implemented by an integral controller and data storage arrangement. Such an arrangement could in fact be located in the housing of the optical detector 11.

5 In Fig. 2 is shown the procedure followed by computer
13. The steps of this procedure are as follows:

Input Data: A set of data is loaded under step 21. In
most applications, each experiment in the set should be
testing (i) the same genetic marker, and (ii) the same set
10 of alleles of that marker, using comparable biochemistry
(e.g. the same reagent batches, etc.). Large data sets help
smooth out noise, although the appropriate size of a data
set depends on the allele frequencies (and thus the number
of expected individuals of each genotypic class). Each data
point in the input data may be thought of as an N-tuple of
15 numeric values, where N is the number of signals collected
from each DNA sample for this locus. (N will usually be the
number of alleles tested at this marker, denoted A, except
when repeated testing is used, in which case N may be
20 greater than A).

Preprocess Data: Next the data are subject to
preprocessing (step 22). An internal M-dimensional Euclidean
representation of the input signals is produced, where each
input datum (an N-tuple) is a point in M-space. Usually, M
25 will be the same as N and the coordinates of the point will
be the values of the input tuple, and thus the preprocessing
will be trivial (although see the first paragraph of
variations discussed). The Euclidean space may be
non-linear, depending on the best available models of signal
30 generation. (Completely mathematically equivalently, any
non-linearity may be embodied in the initial probability
distributions, described below.)

Fig. 3 illustrates preprocessed reaction values from step 22 for GBA locus 177-2 on 80 DNA samples. The X-axis indicates preprocessed reaction values for allele 1 (A) and the Y-axis indicates preprocessed reaction values for allele 2 (T). For clarity, the results of genotype determination are also indicated for each point: Triangles are TT genotype, diamonds are AA, circles are AT, and squares are failures (no signal).

Probability Distributions: Returning to Fig. 2, under step 22, initial probability distributions are established for the G possible genotypes. For example, in a random diploid population containing A tested alleles:

$$G = (A) + (A - 1) + \dots + 1 = \frac{A(A+1)}{2} \quad (1)$$

The initial conditional probability for any hypothetical input datum (a point in M-space, denoted X_i) and genotype (denoted g) is defined as the prior probability of seeing the signal X_i assuming that g is the correct genotype of that datum. That is:

$$\begin{aligned} &\Pr(\text{signal } X_i \cdot \text{Genotype} = g), \\ &\text{where } X_i = (x_1^1 \dots x_1^M) \text{ and } g = \{1 \dots G\} \quad (2) \end{aligned}$$

Figures 4 through 7 illustrate the initial probability distributions established for the data in figure 3. Probability distributions are indicated for the four

genotypic classes of interest, AA, AT, TT and No Signal, in Figs 4, 5, 6, and 7 respectively. The shading at each XY position indicates probability, with darker shades indicating increased probability for hypothetical data points with those X and Y reaction valves.

Exactly where these distributions come from is highly specific to the nature of the input data. The probability distributions can either be pre-computed at this step and stored as quantized data, or can be calculated on the fly as needed in step 23, below. The probability distributions may be fixed, or may be fit to the observed data or may be fit to assumed genotypes as determined by previous iterations of this algorithm. (See Additional Features below.)

Under step 23, we compute the conditional probability of each genotype. For each datum X_i , the above probabilities are collected into an overall conditional posterior probability of each genotype for that datum:

$$\Pr(\text{Genotype} = g \mid \text{Signal } X_i) = \frac{\Pr(\text{Signal } X_i \mid \text{Genotype} = g) \cdot \Pr(\text{Genotype} = g)}{\Pr(\text{Signal } X_i)} \quad (3)$$

where

$\Pr(\text{Genotype} = g)$ is the prior probability of any datum having genotype g ;

$\Pr(\text{Signal } X_i)$ is the prior probability of the signal (a constant which may be ignored); and

$\Pr(\text{Signal } X_i \mid \text{Genotype} = g)$ is the initial probability defined above.

Under step 24, we determine the select the genotype and compute the confidence score. For each datum, using the above posterior probabilities, we determine the most likely genotype assignment g' (the genotype with the highest posterior probability) and its confidence score. The confidence score C is simply the log of the odds ratio:

$$C = \log_{10} \frac{\Pr(\text{Genotype} = g' \mid \text{Signal } X_i)}{\sum_{\text{Genotypes } g} \Pr(\text{Genotype} = g \mid \text{Signal } X_i)} \quad (4)$$

It should be noted that this procedure is significant, among other reasons, because it permits determining a robust probabilistic confidence score associated with each genotype determination.

Under step 25, there may be employed adaptive fitting. A classic iterative adaptive fitting algorithm, such as Estimation-Maximization (E-M), may be used to increase the ability to deal with highly different input data sets and reduce noise sensitivity. In this case, the genotypes computed in step 24 are used to refit the distributions (from step 22). In step 25, a convergence test is performed, which may cause the program to loop back to step 23, but now using the new distributions.

As one example, an E-M search procedure may be used to maximize the total likelihood, that is, to find the maximally likely set of genotype assignments given the input data set. (The net likelihood may be calculated from the Bayesian probabilities, defined above.) For appropriate

5 likelihood calculations and probability distributions, the EM principle will guarantee that this algorithm always produces true-maximum-likelihood values, regardless of initial guess, and that it always converges.

10 Output Data: Under step 26, we output the results (genotypes and confidence scores) to the user or to a computer database. An example of such output is shown in Fig. 8.

Additional Features

15 Additional features may be incorporated into the above procedure. They may be integrated into the procedure either together or separately, and have all been implemented in a preferred embodiment.

20 Preprocessing: During steps 21 or 22, the data (either input tuples or spatial data points) may be preprocessed in order to reduce noise, using any one of many classical statistical or signal-processing techniques. Control data points may be used in this step. In fact, various types of signal filtering or normalizing may be applied at almost any step in the algorithm.

25 Fitting Probability Distributions: The probability distributions calculated in steps 22 and 23 may be fit to the input data - that is, each distribution may be a function of values which are in part calculated from the input data. For example, we may define the conditional
30 probability of a signal point for some genotype to be a function of the distance between that point and the observed mean for that signal.

5 Using an Initial Genotype Guess: In step 22, either a
 simple or heuristic algorithm may be used to produce an
 initial genotype guess for each input data point. If a
 fairly accurate guess can be produced, then the probability
 distributions for each genotype may be fit to the subset of
 10 the data assumed to be of that genotypic class. Another use
 of a genotype guess is in initial input validity checks
 and/or preprocessing (e.g. Step 22), before the remainder of
 the algorithm is applied. To be useful, a guess need not
 produce complete genotypic information, however.

15 Using a Null Genotypic Class: In steps 22 and all
 further steps, one (or more) additional probability
 distributions may be added to fit the data to the signals
 one would expect to see if an experiment (e.g. that datum)
 failed. E.g.,

$$\text{Pr}(\text{signal } X_i \cdot \text{Genotype} \cdot \{1 \dots G\})$$

20 The current implementation above is presently
 restricted to $M=2$ and $N=2 \cdot R$, where R is the number of
 25 repeated tests of both alleles. We refer to the two alleles
 as X and Y . The program understands the notion of "plates"
 of data, a number of which make up a data set.

30 The Initial Guess Variation is employed to initially
 fit distributions using the heuristic described below. The
 Initial Guess is produced during the Preprocessing Step
 which normalizes and background subtracts the input data,
 and remove apparent outlier points as well. These steps are

performed separately for each allele's signal (i.e., 1 dimensional analysis). In fact, this preprocessing is applied separately to each of the R repeated tests, and the test with the small total 2 dimension residual is chosen for use in further steps. Various other preprocessing and post-processing steps are employed for GBA data validation and QC. In particular, controls producing a known reaction value may be employed to assure integrity of the biochemical process. In a preferred embodiment, signals are assumed to be small positive numbers (between 0.0 and 5.0, with 0.0 indicating that allele is likely not present in the sample, and larger values indicating that it may be.

To handle a wide range of input data signal strengths, the Adaptive Fitting Variation is employed. However, the program is hard-coded to perform exactly one or two interactions passes through step 25, which we find works well for existing GBA data.

The probability distributions we fit at present in steps 22 and 25 have as their only parameters (i) the ratio of the X and Y signals for heterozygotes, and (ii) the variance from the normalized means (0.0 negative for that allele, 1.0 for positive for that allele) along each axis separately. In fact, these later numbers are constrained to be at least a fixed minimum, which is rarely exceeded, so that the algorithm will work with very small quantities of data and will produce the behavior we want. These numbers are computed separately for each microtiter plate. The probability distributions are generated using the code

5 (written in C) attached hereto and incorporated herein by reference as Appendix A.

The Null-Class variant is used to provide genotypic class indicating No Signal.

10 Quality control may also be enhanced in a surprising manner using the procedures described here. In particular, the confidence score C of equation (4) serves as a robust indicator of the performance of the biochemical reaction system. For example, a downward trend in the confidence scores within a single batch or in successive batches may indicate deterioration of an important reagent or of a sample or miscalibration of the instrumentation.

15 Accordingly, in a preferred embodiment, the computer may be used to determine the presence of a downward trend in the confidence score over time calculated in reference to each of the following variables: the locus (is there a downward trend in the confidence score of a single locus relative to other loci tested?), the sample (is there a downward trend in the confidence score of a single sample relative to other samples tested?), plate (is there a downward trend in the confidence score of this plate relative to other plate?), and batch (relative to other batches). If a downward trend of statistical significance (using, for example a chi square test) is detected, an alarm condition is entered.

25 Because the confidence score is an accurate indication of the reliability of the reaction system and the genotype determination, a low confidence score associated with a

30

00515178-071300

- 5 given determination is taken as indicating the need for retesting.

09618179.071800

APPENDIX A

```

/* The probability distributions in Figures 4, 5, 6, and 7, respectively,
   correspond to the values of xx_prob, xy_prob, yy_prob, and ns_prob, for
   all possible values of the preprocessed reaction values (x_val and y_val)
   in the range of interest (0.0 to 3.0). */

/* We assume that the following global variables are set... */
double x_pos_mean, x_neg_mean, y_pos_mean, y_neg_mean;
double x_val, y_val;

/* And we set the following globals... */
double xx_prob, xy_prob, yy_prob, ns_prob;

#define POS_VARIANCE          0.25
#define POS_VARIANCE_INCREMENT 0.00
#define NEG_VARIANCE          0.05
#define NEG_VARIANCE_INCREMENT 0.10
#define HET_VARIANCE          0.10
#define HET_VARIANCE_INCREMENT 0.20

#define COND_NEG_PROB(val, given_val, val_mean) \
    normal_prob(val_mean-val, NEG_VARIANCE NEG_VARIANCE_INCREMENT*given_val)

#define COND_HET_PROB(val, given_val) \
    normal_prob(given_val-val, HET_VARIANCE + HET_VARIANCE_INCREMENT)

double normal_prob(deviation, sigma)
double deviation, sigma;
{
    double val=exp(-(deviation*deviation)/(2.0*sigma*sigma));
    return(val>=TINY_PROB ? val : TINY_PROB);
}

void compute_probs()
{
    double x_pos_prob, y_pos_prob, x_neg_prob, y_neg_prob;

    x_pos_prob=normal_prob((x_pos_mean-x_val), POS_VARIANCE);
    x_neg_prob=normal_prob((x_neg_mean-x_val), NEG_VARIANCE);
    y_pos_prob=normal_prob((y_pos_mean-y_val), POS_VARIANCE);
    y_neg_prob=normal_prob((y_neg_mean-y_val), NEG_VARIANCE);

    ns_prob=max(x_neg_prob * COND_NEG_PROB(y_val, x_val, y_neg_mean),
               y_neg_prob * COND_NEG_PROB(x_val, y_val, x_neg_mean));

    xx_prob=x_pos_prob * COND_NEG_PROB(y_val, x_val, y_neg_mean);
    yy_prob=y_pos_prob * COND_NEG_PROB(x_val, y_val, x_neg_mean);
    xy_prob= max(x_pos_prob * COND_HET_PROB(y_val, x_val),
               y_pos_prob * COND_HET_PROB(x_val, y_val));
}

```

09618178-071800

5 (i) reacting the material at the locus to produce a second reaction value independently indicative of the presence of a second allele at the locus;

(ii) forming a second data set including the second reaction value; and

10 (iii) applying the first and second reaction values to each pertinent distribution to determine a measure of the conditional probability of each genotype at the locus.

15 4. A method according to claim 2, further comprising:

(i) reacting the material at the locus to produce a second reaction value;

20 (ii) applying the first and second reaction values to each pertinent distribution to determine the probability of each genotype at the locus; and

(iii) applying the first and second reaction values to each pertinent distribution to determine a measure of the conditional probability of each genotype at the locus.

25 5. A method according to claim 3, wherein each probability distribution associates a hypothetical pair of first and second reaction values with a single probability of each genotype of interest.

30 6. A method according to claim 4, wherein each probability distribution associates a hypothetical pair of

5 first and second reaction values with a single probability
of each genotype of interest.

7. A method according to claim 1, wherein:

10 step (B) includes the step of including in the
data set other reaction values obtained under conditions
comparable to those under which the first reaction value was
produced; and

15 step (C) includes the step of using the reaction
values in the data set to establish the probability
distributions; the method further comprising:

performing steps (D) and (E) with respect to each
of the reaction values.

8. A method according to claim 2, wherein:

20 step (B) includes the step of including in the
data set other reaction values obtained under conditions
comparable to those under which the first reaction value was
produced; and

25 step (C) includes the step of using the reaction
values in the data set to establish the probability
distributions; the method further comprising:

performing steps (D) and (E) with respect to each
of the reaction values.

30 9. A method according to claim 3, wherein:

step (B) includes the step of including in the
data set other reaction values obtained under conditions

5 comparable to those under which the first reaction value was produced; and

step (C) includes the step of using the reaction values in the data set to establish the probability distributions; the method further comprising:

10 performing steps (D) and (E) with respect to each of the reaction values in the first and second data sets.

10. A method according to claim 4, wherein:

15 step (B) includes the step of including in the data set other reaction values obtained under conditions comparable to those under which the first reaction value was produced; and

20 step (C) includes the step of using the reaction values in the data set to establish the probability distributions; the method further comprising:

performing steps (D) and (E) with respect to each of the reaction values in the first and second data sets.

25 11. A method, according to claim 7, of determining the genotype at a locus within genetic material obtained from each of a plurality of samples, the method further comprising:

(1) performing step (A) with respect to the locus of material obtained from each sample;

30 (2) in step (B), including in the data set reaction values obtained from each sample.

5 12. A method according to claim 7, of determining
the genotype of selected loci within genetic material
obtained from a sample, the method further comprising:

(1) performing step (A) at each of the selected
loci;

10 (2) in step (B), including in the data set
reaction values obtained from each of the selected loci.

13. A method according to claim 7, wherein step
(C) includes:

15 (1) establishing a set of initial probability
distributions that associate hypothetical reaction values
with corresponding probabilities for each genotype of
interest at the locus;

20 (2) using the initial probability distributions
to determine measures of the initial conditional probability
for each genotype at the locus; and

25 (3) using the results of step (2) to modify the
initial probability distributions, so that the modified
distributions more accurately reflect the reaction values in
the data set.

14. A method according to claim 8, wherein step
(C) includes:

30 (1) establishing a set of initial probability
distributions that associate hypothetical reaction values
with corresponding probabilities for each genotype of
interest at the locus;

5 (2) using the initial probability distributions to determine measures of the initial conditional probability for each genotype at the locus; and

10 (3) using the results of step (2) to modify the initial probability distributions, so that the modified distributions more accurately reflect the reaction values in the data set.

15 15. A method according to claim 9, wherein step (C) includes:

 (1) establishing a set of initial probability distributions that associate hypothetical reaction values with corresponding probabilities for each genotype of interest at the locus;

20 (2) using the initial probability distributions to determine measures of the initial conditional probability for each genotype at the locus; and

25 (3) using the results of step (2) to modify the initial probability distributions, so that the modified distributions more accurately reflect the reaction values in the data set.

 16. A method according to claim 10, wherein step (C) includes:

30 (1) establishing a set of initial probability distributions that associate hypothetical reaction values with corresponding probabilities for each genotype of interest at the locus;

09513173-071800

5 (2) using the initial probability distributions to determine initial conditional probabilities for each genotype at the locus; and

10 (3) using the results of step (2) to modify the initial probability distributions, so that the modified distributions more accurately reflect the reaction values in the data.

15 17. A method according to claim 13, wherein step (C) further includes:

 (4) repeating steps (1) through (3) a desired number of times.

20 18. A method according to claim 14, wherein step (C) further includes:

 (4) repeating steps (1) through (3) a desired number of times.

25 19. A method according to claim 15, wherein step (C) further includes:

 (4) repeating steps (1) through (3) a desired number of times.

30 20. A method according to claim 16, wherein step (C) further includes:

 (4) repeating steps (1) through (3) a desired number of times.

5 21. A method according to claim 1, wherein step
(E) further includes the step of calculating a confidence
score, associated with the genotype being determined, based
on data obtained from step (D).

10 22. A method according to claim 3, wherein step
(E) further includes the step of calculating a confidence
score, associated with the genotype being determined, based
on data obtained from step (D).

15 23. A method according to claim 7, wherein step
(E) further includes the step of calculating a confidence
score, associated with the genotype being determined, based
on data from step (D), the method further comprising (F)
determining whether a significant downward trend in
20 confidence scores has occurred, and, in such event, entering
an alarm condition.

25 24. A method according to claim 9, wherein step
(E) further includes the step of calculating a confidence
score, associated with the genotype being determined, based
on data from step (D), the method further comprising (F) of
determining whether a significant downward trend in
confidence scores has occurred, and, in such event, entering
an alarm condition.

30 25. A method according to claim 1, wherein each
allele is a single specific nucleotide.

0913173.071800

5 26. A method according to claim 4, wherein each
allele is a single nucleotide.

 27. A method according to claim 1, wherein each
allele consists of at least two specific nucleotides.

10 28. A method according to claim 4, wherein each
allele consists of at least two specific nucleotides.

 29. A method according to claim 1, wherein each
15 allele is defined at least in part by its length in
nucleotides.

 30. A method according to claim 4, wherein each
20 allele is defined at least in part by its length in
nucleotides.

 31. A method according to claim 1, wherein each
allele is defined by one of the presence and absence of at
least one restriction site.

25 32. A method according to claim 4, wherein each
allele is defined by one of the presence and absence of at
least one restriction site.

30 33. A method according to claim 4, wherein step
(B) includes the step of including in the data set reaction
values from prior tests at the locus obtained under

00913178.074800

comparable conditions.

34. A method according to claim 12, wherein the loci are selected on the basis of their ability to discriminate among subjects.

35. A method, according to claim 3, wherein the step A of reacting the material involves using a different reaction from that of step A and the second allele is different from the given allele.

36. A method according to claim 1, wherein step (A) includes the step of assaying for the given allele using genetic bit analysis.

37. A method according to claim 1, wherein step (A) includes the step of assaying for the given allele using hybridization.

38. A method, according to claim 1, wherein step (A) includes the step of assaying for the given allele using allele-specific amplification.

39. A method, according to claim 1, wherein step (A) includes the step of assaying for the given allele using a polymerase chain reaction.

40. A method, according to claim 1, wherein step

5

10

15

20

25

30

45. A method according to claim 42, wherein the

5 loci are selected to provide information pertaining to the
identity of the subject.

46. A method according to claim 42, wherein the
loci are selected to provide information pertaining to
10 matching tissue of the subject with that of a donor.

47. A method according to claim 42, wherein the
loci are spaced throughout the entire genome of the subject
to assist in characterizing the genome of the species of the
subject.

09013178.071800




FIG. 1

09618178-071800




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7

LOCUS#	SUBJECT#	X-VALUE	Y-VALUE	GENOTYPE	CONFIDENCE
177	213-a01	0.176	1.688	TT	8.15
177	213-a02	0.11	2.303	TT	9.41
177	213-a03	0.399	0.575	CT	2.93
177	213-a04	1.02	1.492	CT	9.85
177	213-a05	0.971	1.557	CT	9.99
177	213-a06	0.91	1.513	CT	10
177	213-a07	0.165	1.604	TT	8.33
177	213-a08	1.168	0.173	CC	8.33
177	213-a09	0.158	1.573	TT	8.47
177	213-a10	1.429	0.046	CC	9.44
177	213-a11	1.365	0.047	CC	9.46
177	213-a12	0.186	0.35	NS	1.93
177	213-b01	0.367	0.302	CT	0.03
177	213-b02	0.193	2.019	TT	8.03
177	213-b03	0.138	2.039	TT	8.97
177	213-b04	0.913	1.618	CT	9.99
177	213-b05	0.152	2.111	TT	8.74
177	213-b06	0.308	0.261	NS	1.2
177	213-b07	0.234	1.825	TT	7.14
177	213-b08	0.787	1.321	CT	10
177	213-b09	0.746	1.481	CT	9.73
177	213-b10	1.018	1.423	CT	9.72
177	213-b11	0.897	1.775	CT	9.83
177	213-b12	1.223	0.054	CC	9.44
177	213-c01	0.308	0.513	CT	0.91
177	213-c02	1.594	0.061	CC	9.29
177	213-c03	1.487	0.046	CC	9.42
177	213-c04	0.191	1.998	TT	8.05
177	213-C05	1.395	0.053	CC	9.4
177	213-c06	0.8	1.551	CT	9.79
177	213-c07	0.244	1.973	TT	7.08
177	213-c08	0.504	0.706	CT	4.46
177	213-c09	0.243	1.977	TT	7.11
177	213-c10	0.96	1.831	CT	9.94
177	213-c11	1.43	0.068	CC	9.27
177	213-c12	0.824	1.369	CT	10

FIG.8

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lincoln *et al.*

Attorney Docket: 13020-10

Serial No.: not yet assigned

Examiner (from parent): Fredman, J.

Date Filed: herewith

Group Art Unit (from parent): 1655

For: AUTOMATIC GENOTYPE DETERMINATION

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, NY 10022

July 18, 2000

Assistant Commissioner for Patents
Washington, DC 20231


TRANSMITTAL OF DECLARATION

Sir:

Attached is a copy of the declaration from the grandparent application serial No. 08/362,266. Please note that the power of attorney for Howrey & Simon has been revoked and Kalow Springut & Bressler LLP are now the attorneys of record.

If the Examiner has any questions regarding this matter, or more information is needed, it is respectfully requested that the Examiner contact Applicants' undersigned attorney at the telephone number provided below.

Respectfully submitted,



Franklin S. Abrams
Registration No. 43,457
Attorney for Applicants

Telephone (212)813-1600

T:\PATENTS\Applications\13020-10\trans dec.vwpd

Certificate of Express Mail Under 37 CFR 1.10
I hereby declare that this correspondence is being deposited with the United States Postal Service via Express Mail Label No. EL361953995US in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231

July 18, 2000

Date

Erin McHale

Name

000107.87181626

DECLARATION AND POWER OF ATTORNEY

We, the below named inventors, hereby declare that:

Our residences, post office addresses, and citizenships are as stated below next to our respective names.

We believe we are the original, first, and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled AUTOMATIC GENOTYPE DETERMINATION, the specification of which:

was filed December 22, 1994 as serial no. 08/362,266.

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

We hereby appoint the following attorneys:

Registration No.

Bruce D. Sunstein	27,234
Robert M. Asher	30,445
Timothy M. Murphy	33,198
Harriet M. Strimpel	37,008

all of the firm BROMBERG & SUNSTEIN, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

We request that all correspondence be directed to:

BROMBERG & SUNSTEIN
125 Summer Street
11th Floor
Boston, MA 02110

Attn: Bruce D. Sunstein

and all telephone calls should be directed to:

Bruce D. Sunstein (617) 443-9292

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Stephen E. Lincoln

Full name of first inventor

Stephen

First name

E.

Middle initial

Lincoln

Last name

Inventor's signature: _____

Date: 4/5/95

Country of Citizenship: US

Residence: 325 Limestone Valley Drive, Cockeysville,
Maryland 21030

Post Office Address: same as residence

Michael R. Knapp

Full name of second inventor

Michael

First name

R.

Middle initial

Knapp

Last name

Inventor's signature: _____

Date: 3-30-95

Country of Citizenship: US

Residence: 2630 N. Calvert Street, Baltimore, Maryland 21218

Post Office Address: same as residence

ADDED PAGE TO DECLARATION AND POWER OF ATTORNEY
FOR DIVISIONAL, CONTINUATION, OR CIP APPLICATION


I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information that is material to the examination of this application, namely, information where there is substantial likelihood that a reasonable examiner should consider it important in deciding whether to allow the application to issue as a patent, which occurred between the filing date of the prior application(s).

Prior U.S. application

<u>Serial No.</u>	<u>U.S. Filing Date</u>	<u>Patented</u>	<u>Pending</u>	<u>Abandoned</u>
08/173,173	December 23, 1993		Pending	
07/775,786	October 11, 1991			
07/664,837	March 5, 1991			
08/162,397	December 6, 1993			
08/155,746	November 23, 1993			
08/145,145	November 3, 1993			

[BT38:1407.106]

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available. *Drawings.*

000101079-071800